Tag: ECHELON-1
ASH 2020: ECHELON-1 and ECHELON-2 and other Results with Brentuximab Vedotin
Presentations discussing brentuximab vedotin (Adcetris®; Seagen/Takeda) presented during the 62nd American Society of Hematology (ASH) Annual, Meeting, and Exposition, held virtually from December 5...
U.S. FDA Grants Priority Review for Brentuximab Vedotin in Frontline Advanced...
Based on positive results from the Phase III ECHELON-1 clinical trial, the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental...
Positive Results from Phase III ECHELON-1 Trial Evaluating Brentuximab Vedotin in...
ECHELON-1, a randomized, multicenter, phase III clinical trial evaluating brentiximab vedotin (Adcetris®) as part of a combination chemotherapy regimen in 1,334 patients with advanced...
Patient Enrollment in Phase III ECHELON-2 Clinical Trial of Brentuximab Vedotin...
This week, Seattle Genetics and Takeda Pharmaceutical Co. confirmed that enrollment in the ECHELON-2 clinical trial, a global phase III randomized trial evaluating brentuximab vedotin...
Alcanza Trial Demonstrates Highly Statistically Significant Improvement in Rate of Objective...
Results of the phase III Alcanza trial evaluating brentuximab vedotin (Adcetris®; Takeda Pharmaceutical and Seattle Genetics) in patients with cutaneous T-cell lymphoma (CTCL) shows...
European Commission Approves Brentuximab Vedotin for Consolidation Treatment in Post-Transplant Hodgkin...
The European Commission (EC) has extended the current conditional marketing authorization of brentuximab vedotin (Adcetris®/Seattle Genetics/Takeda Oncology) and approved the drug for the treatment of...
Improving Hodgkin Lymphoma Treatment: Brentuximab Vedotin Data Supports Foundation of...
Final pivotal trial results in relapsed/refractory Hodgkin lymphoma (HL) demonstrate durable remissions lasting more than five years after brentuximab vedotin (Adcetris®; Seattle Genetics) monotherapy. Oral...
